Zoetis Inc. (NYSE:ZTS) Shares Sold by Eastern Bank

Eastern Bank trimmed its position in Zoetis Inc. (NYSE:ZTSGet Rating) by 1.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,075 shares of the company’s stock after selling 91 shares during the quarter. Eastern Bank’s holdings in Zoetis were worth $1,711,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Investment Research & Advisory Group Inc. purchased a new position in Zoetis during the 4th quarter worth $26,000. Amplius Wealth Advisors LLC purchased a new stake in shares of Zoetis in the fourth quarter valued at about $31,000. Aquire Wealth Advisors LLC purchased a new stake in shares of Zoetis in the fourth quarter valued at about $32,000. City State Bank purchased a new stake in shares of Zoetis in the fourth quarter valued at about $36,000. Finally, Mystic Asset Management Inc. purchased a new stake in shares of Zoetis in the fourth quarter valued at about $37,000. 90.73% of the stock is currently owned by institutional investors.

In other news, EVP Roxanne Lagano sold 2,167 shares of the business’s stock in a transaction on Tuesday, April 26th. The shares were sold at an average price of $178.96, for a total transaction of $387,806.32. Following the transaction, the executive vice president now directly owns 23,687 shares of the company’s stock, valued at $4,239,025.52. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Willie M. Reed sold 1,855 shares of the stock in a transaction on Friday, June 10th. The shares were sold at an average price of $162.31, for a total transaction of $301,085.05. Following the transaction, the director now owns 6,782 shares in the company, valued at $1,100,786.42. The disclosure for this sale can be found here. Over the last three months, insiders have sold 8,356 shares of company stock worth $1,447,341. Corporate insiders own 0.12% of the company’s stock.

ZTS traded down $0.26 during trading on Friday, hitting $171.63. 19,992 shares of the company’s stock were exchanged, compared to its average volume of 2,385,739. The company has a current ratio of 2.25, a quick ratio of 1.58 and a debt-to-equity ratio of 1.12. Zoetis Inc. has a 1 year low of $154.18 and a 1 year high of $249.27. The stock has a 50 day moving average price of $167.95 and a 200 day moving average price of $190.58. The firm has a market cap of $80.77 billion, a P/E ratio of 39.70, a price-to-earnings-growth ratio of 2.93 and a beta of 0.77.

Zoetis (NYSE:ZTSGet Rating) last released its quarterly earnings data on Thursday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.10. Zoetis had a net margin of 26.27% and a return on equity of 49.62%. The company had revenue of $2 billion during the quarter, compared to the consensus estimate of $1.98 billion. During the same period in the previous year, the firm earned $1.26 earnings per share. Zoetis’s revenue for the quarter was up 6.9% on a year-over-year basis. Analysts forecast that Zoetis Inc. will post 5.05 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 1st. Stockholders of record on Thursday, July 21st will be given a dividend of $0.325 per share. The ex-dividend date of this dividend is Wednesday, July 20th. This represents a $1.30 dividend on an annualized basis and a dividend yield of 0.76%. Zoetis’s payout ratio is currently 29.82%.

ZTS has been the subject of several recent analyst reports. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 26th. Stifel Nicolaus reduced their price objective on shares of Zoetis from $275.00 to $225.00 and set a “buy” rating for the company in a research note on Friday, June 24th. Citigroup reduced their price objective on shares of Zoetis from $232.00 to $208.00 and set a “neutral” rating for the company in a research note on Wednesday, March 9th. Finally, The Goldman Sachs Group cut their target price on shares of Zoetis from $237.00 to $208.00 and set a “buy” rating for the company in a research report on Thursday, May 19th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $229.75.

Zoetis Profile (Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Recommended Stories

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSGet Rating).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.